HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reckitt Not Worried By Q4 Stumble At 'Jewel' OTC Business

Executive Summary

As it felt the effects of a weaker cold & flu season, Reckitt insisted its subdued Q4 showing is not an indicator of how its Health business will perform in 2024. The unit is expected to deliver mid single-digit growth, as it did last year.

You may also be interested in...



Haleon Surprises Analysts With Stand-Out Cold & Flu Showing In Q4

In describing Haleon’s Q4 showing as a “strong finish to the year,” Bernstein’s Bruno Monteyne pointed to “remarkable strength in respiratory health,” with the category resoundingly beating analysts’ consensus estimates of a 2.5% decline.

UK Proposes Accelerating Authorizations Of Novel Supplements Like CBD

UK Food Standards Agency proposes shaving a minimum of three months off novel food authorization procedure as part of wider plans to shake-up the process for products like CBD supplements.

Poland's President Blocks Rx-To-OTC Switch Of Emergency Contraceptive Pill

Citing a will to protect children's health, Poland's president has blocked a bill which would have restored OTC access to the morning after pill to those aged 15 and above. In response, the health ministry has drawn up a proposal to allow pharmacists to issue prescriptions for emergency contraception.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel